Roche still resilient to biosimilars, but 2016 sales and profit just miss

1 February 2017

Swiss pharma giant Roche (ROG: SIX) posted full-year 2016 financial results this morning, showing group sales up 4% at constant exchange rates (+5% Swiss francs) at 50.58 billion Swiss francs ($50.68), just missing analysts’ expectations of 50.7 billion francs.

Pharmaceutical Division sales were up 3% (+5% SwF) at 39.20 billion francs, with several of its top-selling drugs continuing to prosper amid less generic competition than those of its rivals. Diagnostics Division sales were 11.47 billion francs, a rise of 7% (+6% SwF).

Core operating profit came in at 18.42 billion francs, a rise of 4% (+5% SwF) and core earnings per share were 14.53, a rise of 5% (+8% SwF). Core net income in 2016 rose to 12.7 billion francs, Roche said, slightly below the 12.8 billion franc average estimate by analysts in a Reuters poll. Roche shares up 1.37% at 236.00 francs in morning trading.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK